PNC Financial Services Group Inc. Sells 26,630 Shares of Zoetis Inc. $ZTS

PNC Financial Services Group Inc. decreased its position in Zoetis Inc. (NYSE:ZTS) by 11.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 213,281 shares of the company’s stock after selling 26,630 shares during the quarter. PNC Financial Services Group Inc.’s holdings in Zoetis were worth $26,835,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in ZTS. Brighton Jones LLC grew its holdings in shares of Zoetis by 180.4% in the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock worth $754,000 after purchasing an additional 2,978 shares during the last quarter. Empowered Funds LLC grew its holdings in shares of Zoetis by 6.2% in the 1st quarter. Empowered Funds LLC now owns 11,293 shares of the company’s stock worth $1,859,000 after purchasing an additional 657 shares during the last quarter. Intech Investment Management LLC grew its holdings in shares of Zoetis by 17.2% in the 1st quarter. Intech Investment Management LLC now owns 8,347 shares of the company’s stock worth $1,374,000 after purchasing an additional 1,224 shares during the last quarter. Sivia Capital Partners LLC grew its holdings in shares of Zoetis by 73.8% in the 2nd quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company’s stock worth $522,000 after purchasing an additional 1,422 shares during the last quarter. Finally, Glenview Trust co grew its holdings in shares of Zoetis by 11.8% in the 2nd quarter. Glenview Trust co now owns 4,780 shares of the company’s stock worth $745,000 after purchasing an additional 506 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Up 1.5%

Shares of NYSE ZTS opened at $81.26 on Friday. The firm’s 50-day simple moving average is $108.11 and its 200 day simple moving average is $118.65. The company has a market cap of $34.06 billion, a price-to-earnings ratio of 13.48, a price-to-earnings-growth ratio of 1.31 and a beta of 0.87. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80. Zoetis Inc. has a 12-month low of $72.38 and a 12-month high of $172.23.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.60 by ($0.07). The company had revenue of $2.26 billion for the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The firm’s quarterly revenue was up 2.9% on a year-over-year basis. During the same quarter last year, the company earned $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, research analysts expect that Zoetis Inc. will post 6.88 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be given a dividend of $0.53 per share. The ex-dividend date is Monday, July 20th. This represents a $2.12 annualized dividend and a yield of 2.6%. Zoetis’s dividend payout ratio is 35.16%.

Insider Buying and Selling

In other Zoetis news, Director Michael B. Mccallister bought 3,000 shares of the business’s stock in a transaction on Monday, May 11th. The shares were bought at an average cost of $77.76 per share, for a total transaction of $233,280.00. Following the transaction, the director owned 24,524 shares in the company, valued at approximately $1,906,986.24. This trade represents a 13.94% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Paul Bisaro bought 2,000 shares of the business’s stock in a transaction on Wednesday, May 13th. The shares were acquired at an average price of $75.88 per share, for a total transaction of $151,760.00. Following the completion of the transaction, the director owned 27,862 shares in the company, valued at approximately $2,114,168.56. This trade represents a 7.73% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased a total of 11,650 shares of company stock worth $886,384 in the last 90 days. Corporate insiders own 0.22% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on ZTS. Weiss Ratings lowered shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, March 27th. Bank of America upped their target price on shares of Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a report on Friday, February 13th. UBS Group lowered their target price on shares of Zoetis from $130.00 to $99.00 and set a “neutral” rating on the stock in a report on Friday, May 8th. Citigroup lowered their target price on shares of Zoetis from $145.00 to $112.00 and set a “buy” rating on the stock in a report on Monday, May 18th. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $115.00 target price on shares of Zoetis in a report on Friday, May 15th. Seven research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Zoetis presently has a consensus rating of “Hold” and an average target price of $133.92.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.